Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Omvoh. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 1 application for Mirikizumab-mrkz (sold as Omvoh), first approved Oct 26, 2023, with 2 new uses approved and 1 published complete response letter.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Omvoh Pen
Part D
$12.6M
+201%
192
Omvoh
Part B
$8.0M
+600%
134
Omvoh
Part D
$3.4M
+204%
70
Medicaid spending
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Omvoh
$7.5M for 626 prescriptions, +218% on 2024
How its trials ended
20 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Of the 8 whose ending is known, 88% met their primary endpoint, 0% missed it and 13% stopped early.
Met its primary endpoint735%Met its primary endpointCount7Share35%
Ongoing735%OngoingCount7Share35%
Completed, result not reported525%Completed, result not reportedCount5Share25%
Stopped: sponsor or business decision15%Stopped: sponsor or business decisionCount1Share5%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
First approved in Japan 7 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
OmvohA drug with a new indication and a new dosage for the treatment of moderate to severe active Crohn's disease (for use only in patients who have not… · Eli Lilly Japan K.K. · Mar 27, 2025
Omvoh, new ingredientA drug with a new active ingredient indicated for the remission induction therapy of moderate to severe ulcerative colitis (for use only in patients who… · Eli Lilly Japan K.K. · Mar 27, 2023 · Review report
Approvals in Canada (Health Canada)
First approved in Canada 3 months before the US. New drug submissions since 1994, matched by ingredient; see all Canadian approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA